We are live on ! Find out more
ABMD

Abiomed Inc

Delisted

ABMD was delisted on the 21st of December, 2022.

559 hedge funds and large institutions have $11.4B invested in Abiomed Inc in 2019 Q1 according to their latest regulatory filings, with 88 funds opening new positions, 213 increasing their positions, 188 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

66% more first-time investments, than exits

New positions opened: 88 | Existing positions closed: 53

13% more repeat investments, than reductions

Existing positions increased: 213 | Existing positions reduced: 188

6% more funds holding

Funds holding: 529559 (+30)

11% less capital invested

Capital invested by funds: $12.8B → $11.4B (-$1.45B)

45% less call options, than puts

Call options by funds: $165M | Put options by funds: $300M

54% less funds holding in top 10

Funds holding in top 10: 136 (-7)

Holders
559
Holders Change
+30
Holders Change %
+5.67%
% of All Funds
12.1%
Holding in Top 10
6
Holding in Top 10 Change
-7
Holding in Top 10 Change %
-53.85%
% of All Funds
0.13%
New
88
Increased
213
Reduced
188
Closed
53
Calls
$165M
Puts
$300M
Net Calls
-$135M
Net Calls Change
-$50.5M

ABMD Hedge Fund Activity: Q1 2019 in Review

559 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Abiomed Inc (ABMD) for Q1 2019, worth a combined $11.4B — down 11% from $12.8B a quarter earlier.

Buyers outnumbered sellers: 88 funds opened new ABMD positions and 53 closed out — a net gain of 35 holders — while 213 added to existing stakes and 188 trimmed.

The largest buyer was Amundi Asset Management US, adding an estimated $163M. The largest seller was Winslow Capital Management, exiting entirely with an estimated $170M sold.

  • 559 institutional investors held Abiomed Inc (ABMD) as of Q1 2019, up from 529 in Q4 2018.
  • Funds reported $11.4B of Abiomed Inc stock for Q1 2019, down 11% quarter-over-quarter.
  • 88 funds opened new Abiomed Inc positions in Q1 2019 and 53 closed out, a net change of +35 holders.
  • The largest Abiomed Inc buyer in Q1 2019 was Amundi Asset Management US, an estimated $163M added.
  • The largest Abiomed Inc seller in Q1 2019 was Winslow Capital Management, an estimated $170M sold.

Based on aggregated 13F filings for Q1 2019.